6.74
0.40 (6.31%)
| Penutupan Terdahulu | 6.34 |
| Buka | 6.35 |
| Jumlah Dagangan | 631,028 |
| Purata Dagangan (3B) | 1,078,211 |
| Modal Pasaran | 417,370,112 |
| Harga / Jualan (P/S) | 2.12 |
| Harga / Buku (P/B) | 0.740 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Keuntungan | -198.84% |
| Margin Operasi (TTM) | -182.09% |
| EPS Cair (TTM) | -8.91 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 67.12% |
| Nisbah Semasa (MRQ) | 4.88 |
| Aliran Tunai Operasi (OCF TTM) | -281.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -185.65 M |
| Pulangan Atas Aset (ROA TTM) | -16.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ginkgo Bioworks Holdings, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.63 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.88% |
| % Dimiliki oleh Institusi | 77.96% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Anchorage Capital Group, L.L.C. | 31 Dec 2025 | 1,746,363 |
| Forbes J M & Co Llp | 31 Dec 2025 | 1,040,441 |
| Prescott Group Capital Management, L.L.C. | 31 Dec 2025 | 541,845 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 12.00 (TD Cowen, 78.04%) | Beli |
| Median | 8.50 (26.11%) | |
| Rendah | 5.00 (BTIG, -25.82%) | Jual |
| Purata | 8.50 (26.11%) | |
| Jumlah | 1 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 7.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 12 Mar 2026 | 5.00 (-25.82%) | Jual | 6.74 |
| TD Cowen | 08 Jan 2026 | 12.00 (78.04%) | Beli | 9.06 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark |
| 13 Jan 2026 | Pengumuman | Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference |
| 22 Dec 2025 | Pengumuman | Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach |
| 17 Dec 2025 | Pengumuman | Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |